The dissertation covers the field of competitive collaboration by focusing on Joint Ventures. It identifies the strategic usefulness for multinational companies by evaluating critical success factors and pre-conditions. Due to increasing pressure from the business environment the trend of competitive collaboration has accelerated. In this context, Joint Ventures were identified as a potential field of investigation. The apparent contradiction of cooperating with a competitor evoked the discussion of potential risks. It was questionable whether
companies do so loose some of its sovereignty. This question created the incentive to identify essential requirements when forming a Joint Venture. By analysing the available literature, Joint Ventures were identified as a strategic tool for multinational companies to achieve competitive advantage. It was outlined that the risks that come along with competitive collaboration can be minimized if the preconditions of Joint Venture creation are considered adequately. Moreover, the analysis clarified the need for explicit responsibilities for each sub-process when forming a Joint Venture. The analysis of a specific case highlighted the essential learning potential from past cooperations in order to succeed over the long term.
Finally, the analysis showed that well structured and re-arranged measures leverage the benefits of competitive collaboration. It was identified, that a loss of sovereignty only occurs if the alliance is managed poorly. It was recommended that a three stage model, including the sub-processes “alliance
planning”, “partner selection” and “alliance structure and management”, should be implemented to generalise the process of alliance management. Moreover, setting a focus on strategic and cultural compatibility between the partners was evaluated as
being important to maintain the health of the alliance over the long term. The dissertation outlined that especially multinational companies, whose strategy considerably depends on alliance partners, should strive to institutionalise the
alliance management. Finally it was recommended, that gatekeepers should be implemented rather than abolished. A controlled flow of information and the importance of keeping each company’s ompetitive advantage were seen as being essential.
Table of Contents
1 Introduction
1.1 Aims
1.2 Limitations
2 Literature review of Strategic Alliances and Joint Ventures
2.1 Choosing a partner – The collaboration with a competitor
2.1.1 Principles for competitive collaboration
2.1.2 Durability of the cooperation
2.1.3 Outcome when collaborating with a competitor
2.2 Strategic Alliances
2.2.1 SAs as a strategy for multinational businesses
2.2.2 Benefits of Strategic Alliances
2.2.3 Costs and risks when forming a Strategic Alliance
2.2.4 The need for a new management style
2.2.5 Range of Strategic Alliances
2.2.6 The role of Joint Ventures
2.3 Structuring the Joint Venture for a multinational strategy
2.3.1 The Joint Venture in a multinational perspective
2.3.2 A definition of Joint Ventures
2.3.3 The process of structuring a Joint Ventures
2.3.4 The Joint Venture checklist
2.3.5 Principles and reasons for Joint Venture creation
2.3.6 Risks and costs of Joint Ventures
2.4 Concluding JVs
3 Methodology
3.1 Research methods
3.2 Secondary Data
3.3 Primary Data
3.3.1 Analysis of a case study
3.3.2 Analysis of derived findings
4 Evaluation of a case study and derived findings
4.1 Eli Lilly-Ranbaxy Private Limited (ELR)
4.1.1 Eli Lilly and Company
4.1.2 Ranbaxy Laboratories Ltd.
4.1.3 Joint Venture formation
4.1.4 Upcoming challenges for the Joint Venture
4.1.5 Reasons for building the Eli Lilly-Ranbaxy Private Limited
4.1.6 Occurring risks during the Joint Venture arrangement
4.1.7 Outcome for Eli Lilly Company
4.1.8 Outcome for Ranbaxy Laboratories Ltd.
4.1.9 Concluding the ELR Joint Venture
4.1.10 The ELR JV as a role model
4.2 Eli Lilly’s framework for structuring alliance formation
4.2.1 An overview of Eli Lilly’s partnership approach
4.2.2 Corporate Business Development at Eli Lilly (Get it)
4.2.3 Office of Alliance Management at Eli Lilly (Create Value)
4.2.4 Putting principles into practice
4.2.5 Concluding Lilly’s Alliance Management approach
5 Conclusion
6 Recommendations
Research Objectives and Themes
The primary aim of this dissertation is to evaluate the strategic importance of Joint Ventures (JVs) for multinational companies and to establish how these alliances can be managed effectively to achieve competitive advantage while minimizing associated risks.
- Strategic role of Joint Ventures in multinational businesses
- Methods for structuring alliances and mitigating cooperation risks
- Analysis of the Eli Lilly-Ranbaxy Joint Venture as a practical case study
- Frameworks for institutionalizing alliance management processes
- Importance of cultural and strategic compatibility in long-term partnerships
Excerpt from the Book
4.1.6 Occurring risks during the Joint Venture arrangement
When the JV developed from the beginning of 1993 onwards it became clear that both companies had a lot in common. They both believed in high ethical standards, in technology and innovation (Celly et al. 2004). While Eli Lilly was focusing on marketing its drugs in the Indian market, Ranbaxy was concentrating on gaining key knowledge from its western partner.
However, some risks appeared that challenged the cohesive cooperation. As Lilly supplied the ELR with necessary products for the Indian market, the danger of absorption of knowledge by the Indian partner occurred. On the one hand this was especially concerning Lilly’s patented product range and on the other hand the danger of loosing to much key knowledge in the field of marketing and sales. Referring to the theory of JV creation this can be seen as a major drawback of competitive collaboration (Bartlett et al. 2008). Although Ranbaxy was focused on generic drugs instead of innovative and patented drugs, they could use this knowledge over the long term in order to find new competitive advantages, thereby becoming a direct competitor for Lilly (Bartlett et al. 2008). Hence, especially Lilly was urged to be careful in order to hide key knowledge to some extent.
Another important risk, which challenged the ELR, could be seen in a possible failing cooperation of different organisational cultures (Bleeke and Ernst 1993). As the partners came from different continents with a different cultural background the danger of clashing cultures was extremely high. However, a common basis was recognised directly at the beginning (Celly et al. 2004). Both companies had a lot in common, for instance the treatment of their employees. They both believed that their employees had to be treated fairly and with respect in order to gain high commitment
Summary of Chapters
1 Introduction: Provides an overview of the shifting business environment and the rising necessity for strategic alliances as a tool for competitive advantage.
2 Literature review of Strategic Alliances and Joint Ventures: Examines theoretical foundations, benefits, and risks associated with strategic alliances, while defining the specific role of Joint Ventures.
3 Methodology: Details the research approach, including the analysis of secondary data and the representative case study of Eli Lilly and Ranbaxy.
4 Evaluation of a case study and derived findings: Conducts an in-depth analysis of the Eli Lilly-Ranbaxy Joint Venture and evaluates Eli Lilly’s subsequent framework for alliance management.
5 Conclusion: Summarizes the key insights, confirming that structured Joint Venture creation is a vital strategy for multinational companies to gain competitive advantage.
6 Recommendations: Offers practical guidance for multinational companies on implementing structured alliance management processes and maintaining long-term partnership health.
Keywords
Joint Ventures, Strategic Alliances, Competitive Advantage, Multinational Companies, Eli Lilly, Ranbaxy, Alliance Management, Corporate Strategy, Market Entry, Cultural Compatibility, Risk Mitigation, Partner Selection, Knowledge Transfer, Business Development, Organizational Learning
Frequently Asked Questions
What is the primary focus of this dissertation?
The work examines Joint Ventures as a strategic tool for multinational companies, analyzing their potential for achieving competitive advantage and identifying essential management factors.
What are the core thematic areas?
The core themes include the theory of competitive collaboration, the lifecycle of strategic alliances, the classification of joint ventures, and the institutionalization of alliance management.
What is the central research question?
The research explores how multinational companies can leverage Joint Ventures to reach competitive goals while managing the inherent risks of cooperating with competitors.
Which scientific methodology is used?
The dissertation employs a literature review based on academic sources and a case study approach, evaluating the Eli Lilly-Ranbaxy Joint Venture and internal company documentation.
What topics are covered in the main body?
The main body covers the literature on Strategic Alliances, the structural process of forming JVs (planning, selection, management), and a detailed case analysis of Eli Lilly's partnership practices.
Which keywords best characterize this work?
Key terms include Joint Ventures, Strategic Alliances, Competitive Advantage, Alliance Management, Eli Lilly, and Corporate Strategy.
How does the Eli Lilly case study illustrate the theory?
The case study demonstrates the practical challenges of cultural and strategic alignment, showing how Eli Lilly evolved its alliance management processes after the termination of the ELR joint venture.
Why are gatekeepers considered critical in this research?
The research discusses gatekeepers as essential for controlling the flow of information to prevent the unwanted transfer of core capabilities while still enabling effective collaboration.
- Quote paper
- Volker Küpper (Author), 2008, The use of Joint Ventures as a strategic tool for multinational companies, Munich, GRIN Verlag, https://www.grin.com/document/127943
